美股市场个股详情

BLUE bluebird bio

添加自选

0.900
-0.004-0.39%

收盘价 05/03 16:00 (美东)

0.900
+0.000+0.03%

盘后 16:53 (美东)

1.73亿总市值-1428市盈率TTM

bluebird bio股票讨论区

登录发表评论

牛奔

03/19 00:32

股票融资意味着总股本增加，变相不值钱，不要几天这支股票肯定跌

Trytosaveabit

03/18 20:03

News

$bluebird bio(BLUE.US)$ bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
3 MINUTES AGO, 8:00 AM EDT
VIA BUSINESSWIRE

Trytosaveabit

02/28 04:19

$bluebird bio(BLUE.US)$ With all the 13G and G/A filed recently. Im thinking that news of LOVO-CEL Commercial launch could be coming soon? That sure would increase the company’s financial position! Hehehe

Moomoo AI

02/27 22:43

Recent insider selling at bluebird bio, lack of insider buying, and low insider ownership raise caution. The company has 3 warning signs, 2 of which are concerning. bluebird bio may not be the best stock to buy.

Bluebird Bio Insiders Miss 33% Gain After Offloading Stock

Like this new 13G filed!

$bluebird bio(BLUE.US)$ 13G: Statement of acquisition of beneficial ownership by individuals-THE GOLDMAN SACHS GROUP, INC.(6.4 %),GOLDMAN SACHS & CO. LLC(6.4 %)

Trytosaveabit

01/17 20:18

Update

$bluebird bio(BLUE.US)$ Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
Benzinga· 2 mins ago

Trytosaveabit

01/08 21:18

Update

$bluebird bio(BLUE.US)$ Bluebird Bio Provides Update; Sees Prelim. Unaudited Cash And Cash Equivalents ~$275M
Benzinga· 3 mins ago
Significant momentum behind LYFGENIA launch with 35 Qualified Treatment Centers accepting patient referrals and payer agreements in place covering approximately 200 million U.S. lives
Anticipate 85 to 105 patient starts (cell collections) across commercial portfolio in 2024 with first patient start for LYFGENIA expected in Q1 2024
Cash, cash equivalents and mar...

Trytosaveabit

01/04 21:13

Update

$bluebird bio(BLUE.US)$ Bluebird Bio Has Signed A Second Outcomes-Based Agreement For LYFGENIA, Bringing The Total Number Of Covered Lives To ~200M, And Will Provide Updates On The Commercial Launch At The 42nd Annual J.P. Morgan Healthcare Conference